Developer docs
API playgroundTry for free, no card

Search company profiles

FibriCheck

Full company profile

uuid0000wus

Namestring
FibriCheck
Legal namestring
FibriCheck
Websiteurl
fibricheck.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

FibriCheck is an FDA-cleared medical device company that provides smartphone-based heart rhythm monitoring using photoplethysmography (PPG) technology. Founded in 2014 and operationally based in Limburg, Belgium with US headquarters in New York, the company enables patients to capture 60-second heart rhythm measurements via their existing smartphone camera, with results analyzed by a clinically validated AI algorithm reporting 98.5% accuracy for atrial fibrillation detection. The platform serves healthcare providers, health systems, health plans, and individual patients globally, with cumulative deployment of over 1.3 million patients monitored and 40 million rhythm strips analyzed to date, supported by more than 100 peer-reviewed publications and FDA 510(k) clearance as a Software-as-a-Medical-Device.

The product ecosystem consists of four integrated components: a patient-facing smartphone application, clinical reports with AF load and symptom correlation, a provider portal for patient data review and alert management, and an API enabling integration into existing Electronic Health Record (EHR), Remote Patient Monitoring (RPM), and population health platforms. Distribution spans direct enterprise sales to healthcare systems and health plans, API-based healthcare IT integration, and a direct-to-consumer smartphone app channel.

FibriCheck operates a B2B and B2B2C business model selling enterprise subscriptions to healthcare providers and payors, with deployment enabled through RPM reimbursement pathways. Pricing is quote-based and not publicly disclosed. The company has raised approximately $12.7M in disclosed funding across rounds from 2014 to 2020, with subsequent non-dilutive support from accelerator programs including MedTech Innovator (2024) and HeartX Cardiovascular Accelerator (2025).

Short descriptiontext

FibriCheck provides FDA-cleared, smartphone-based heart rhythm monitoring using PPG technology and a clinically validated AI algorithm, serving healthcare providers, health systems, health plans, and patients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHasselt, Belgium
HQ citystring
Hasselt
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote cardiac monitoring, heart rhythm analysis, atrial fibrillation detection, smartphone PPG monitoring, digital health SaMD
Industry3 codes
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Remote Cardiac Monitoring Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Remote Patient Monitoring (RPM) Reimbursement
TypeSubscription Recurring
Description

FibriCheck operates within RPM reimbursement pathways, enabling healthcare providers and health systems to deploy the technology and bill through existing Remote Patient Monitoring codes. The company has reimbursement pathways already in place.

fibricheck.us
2Healthcare System & Health Plan Contracts
TypeSubscription Recurring
Description

Direct contracts with healthcare systems, health plans, and providers for deployment of the heart rhythm monitoring ecosystem across clinical programs.

fibricheck.us
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Quote-based enterprise pricing for healthcare organizations
ModelSubscriptionBilling cadenceMonthly
Notes

Quote-based / Not publicly disclosed. Healthcare systems, health plans, and providers contact the company directly for pricing. RPM reimbursement pathways referenced.

fibricheck.us
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

FibriCheck provides an FDA-cleared, smartphone-based heart rhythm monitoring ecosystem that uses photoplethysmography (PPG) signals captured via the smartphone camera to detect atrial fibrillation and other arrhythmias. The offering combines a patient-facing mobile application for 60-second measurements, a clinically validated AI algorithm with 98.5% accuracy for AF detection, a web-based Provider Portal for clinical review and alert management, and an API for integration into EHRs, RPM platforms, and population health systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98.5% accuracy for AF detection
+3 more records
Product overview1 text field

FibriCheck is a complete heart rhythm monitoring ecosystem consisting of four integrated components: a patient-facing smartphone application (FibriCheck Mobile Application) that uses the device camera for 60-second PPG-based measurements, Clinical Reports delivering summarized rhythm analysis and AF load metrics, a Provider Portal for healthcare professionals to review data and manage alerts, and an EHR & Platform API enabling integration with existing healthcare IT systems. The ecosystem is powered by a clinically validated AI algorithm providing 98.5% accuracy for AF detection.

Product and service1 record
1FibriCheck Mobile Application
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1HeartX Cardiovascular Accelerator
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

FibriCheck is supported by the HeartX Cardiovascular Accelerator, which announced the company among seven startup companies selected for its 2025 program focusing on innovative cardiovascular healthcare solutions.

fibricheck.us
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NHS Foundation Trust using FibriCheck for remote heart rhythm monitoring, enabling patients to take readings at home and reducing unnecessary hospital visits. Lead Arrhythmia Nurse Specialist Sharon Toora quoted endorsing the technology.

Strategic tierCoreTypeTechnology or Integration
Description

API-based integration partnerships with EHR systems, RPM platforms, and population health systems for seamless clinical workflow integration and deployment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Fitbit's PPG-based Irregular Heart Rhythm notifications and ECG app target the same general AF screening use case at the consumer/wellness tier, and Google's ownership adds AI/clinical research scale FibriCheck must compete with indirectly.

TypeDirect peer
Description

iRhythm's Zio patch provides ambulatory ECG monitoring with AI analysis, competing for the same cardiology-prescribed monitoring budget and clinical workflow that FibriCheck addresses with its PPG smartphone alternative.

TypeDirect peer
Description

AliveCor's KardiaMobile is a smartphone/portable ECG device with FDA-cleared AF detection algorithms targeting the same patient-and-provider workflow that FibriCheck serves. It is the closest direct competitor in the smartphone-enabled cardiac rhythm monitoring space.

TypeBroad incumbent
Description

Withings offers connected health devices including ECG-equipped smartwatches and BPM Core, with FDA-cleared AF detection. It competes for both the consumer heart-monitoring buyer and the clinician-prescribed remote monitoring use case.

TypeBroad incumbent
Description

Apple Watch ships FDA-cleared PPG-based irregular rhythm and ECG features to a global consumer installed base. While not a clinical RPM platform, it dominates consumer AF detection mindshare and pressures FibriCheck's DTC channel.

TypeDirect peer
Description

Eko builds FDA-cleared AI-enabled cardiac monitoring tools (digital stethoscope + handheld ECG) with AI algorithms for AF and murmur detection, overlapping FibriCheck's clinical-grade AI cardiac screening positioning.

TypeEmerging player
Description

Cardiologs offers AI-powered ECG analysis software used by clinicians for arrhythmia detection, integrated into Philips' cardiac monitoring portfolio. It overlaps with FibriCheck's provider-facing AI rhythm interpretation layer.

TypeDirect peer
Description

Preventice (now part of Boston Scientific) provides remote cardiac monitoring patches and services with AI-driven arrhythmia detection, competing head-to-head with FibriCheck for health system remote monitoring spend.

TypeDirect peer
Description

BioTel (formerly BioTelemetry, part of Philips) provides ambulatory cardiac monitoring services (MCOT, Holter) with AI-assisted reporting. It competes directly for cardiology practice and health system remote monitoring contracts.

TypeRegional player
Description

Huawei smartwatches ship PPG-based heart rhythm and ECG features with regulatory approvals in Europe and parts of Asia. It is a comparable PPG-AF wearable play but does not directly target FibriCheck's clinical RPM channel in the US.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FibriCheck

Remote Cardiac Monitoring Softwarefibricheck.com

FibriCheck provides FDA-cleared, smartphone-based heart rhythm monitoring using PPG technology and a clinically validated AI algorithm, serving healthcare providers, health systems, health plans, and patients globally.

What FibriCheck does

FibriCheck is an FDA-cleared medical device company that provides smartphone-based heart rhythm monitoring using photoplethysmography (PPG) technology. Founded in 2014 and operationally based in Limburg, Belgium with US headquarters in New York, the company enables patients to capture 60-second heart rhythm measurements via their existing smartphone camera, with results analyzed by a clinically validated AI algorithm reporting 98.5% accuracy for atrial fibrillation detection. The platform serves healthcare providers, health systems, health plans, and individual patients globally, with cumulative deployment of over 1.3 million patients monitored and 40 million rhythm strips analyzed to date, supported by more than 100 peer-reviewed publications and FDA 510(k) clearance as a Software-as-a-Medical-Device.

The product ecosystem consists of four integrated components: a patient-facing smartphone application, clinical reports with AF load and symptom correlation, a provider portal for patient data review and alert management, and an API enabling integration into existing Electronic Health Record (EHR), Remote Patient Monitoring (RPM), and population health platforms. Distribution spans direct enterprise sales to healthcare systems and health plans, API-based healthcare IT integration, and a direct-to-consumer smartphone app channel.

FibriCheck operates a B2B and B2B2C business model selling enterprise subscriptions to healthcare providers and payors, with deployment enabled through RPM reimbursement pathways. Pricing is quote-based and not publicly disclosed. The company has raised approximately $12.7M in disclosed funding across rounds from 2014 to 2020, with subsequent non-dilutive support from accelerator programs including MedTech Innovator (2024) and HeartX Cardiovascular Accelerator (2025).

FibriCheck firmographics

Firmographics
Name
FibriCheck
Legal name
FibriCheck
Website
https://fibricheck.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
FibriCheck provides FDA-cleared, smartphone-based heart rhythm monitoring using PPG technology and a clinically validated AI algorithm, serving healthcare providers, health systems, health plans, and patients globally.
Ownership category
akta.pro rank

FibriCheck industry classification

Industry
Product category
Remote Cardiac Monitoring Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Remote cardiac monitoring
  • Heart rhythm analysis
  • Atrial fibrillation detection
  • Smartphone PPG monitoring
  • Digital health SaMD

Where FibriCheck is headquartered

Location

Headquarters

HQ city
Hasselt
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

FibriCheck business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Remote Patient Monitoring (RPM) Reimbursement: FibriCheck operates within RPM reimbursement pathways, enabling healthcare providers and health systems to deploy the technology and bill through existing Remote Patient Monitoring codes. The company has reimbursement pathways already in place.
  2. Healthcare System & Health Plan Contracts: Direct contracts with healthcare systems, health plans, and providers for deployment of the heart rhythm monitoring ecosystem across clinical programs.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyQuote-based enterprise pricing for healthcare organizations

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

FibriCheck product offering

Product offering

Core offering

FibriCheck provides an FDA-cleared, smartphone-based heart rhythm monitoring ecosystem that uses photoplethysmography (PPG) signals captured via the smartphone camera to detect atrial fibrillation and other arrhythmias. The offering combines a patient-facing mobile application for 60-second measurements, a clinically validated AI algorithm with 98.5% accuracy for AF detection, a web-based Provider Portal for clinical review and alert management, and an API for integration into EHRs, RPM platforms, and population health systems.

Product overview

FibriCheck is a complete heart rhythm monitoring ecosystem consisting of four integrated components: a patient-facing smartphone application (FibriCheck Mobile Application) that uses the device camera for 60-second PPG-based measurements, Clinical Reports delivering summarized rhythm analysis and AF load metrics, a Provider Portal for healthcare professionals to review data and manage alerts, and an EHR & Platform API enabling integration with existing healthcare IT systems. The ecosystem is powered by a clinically validated AI algorithm providing 98.5% accuracy for AF detection.

Differentiator

Problem solved

Functional benefit

Products and services

  • FibriCheck Mobile Application

Quantifiable outcome

  • 98.5% accuracy for AF detection
  • +3 more outcomes

Companies that use FibriCheck

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

FibriCheck technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

FibriCheck partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • HeartX Cardiovascular AcceleratorcoreStrategic or Co-development Partner · 1 January 2025FibriCheck is supported by the HeartX Cardiovascular Accelerator, which announced the company among seven startup companies selected for its 2025 program focusing on innovative cardiovascular healthcare solutions.
  • Mid and South Essex NHS Foundation TrustcoreStrategic or Co-development PartnerNHS Foundation Trust using FibriCheck for remote heart rhythm monitoring, enabling patients to take readings at home and reducing unnecessary hospital visits. Lead Arrhythmia Nurse Specialist Sharon Toora quoted endorsing the technology.
  • EHR & RPM Platform IntegrationscoreTechnology or IntegrationAPI-based integration partnerships with EHR systems, RPM platforms, and population health systems for seamless clinical workflow integration and deployment.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

FibriCheck competitors and assessment

Company assessment

Broad incumbents

  • Fitbit (Google): Fitbit's PPG-based Irregular Heart Rhythm notifications and ECG app target the same general AF screening use case at the consumer/wellness tier, and Google's ownership adds AI/clinical research scale FibriCheck must compete with indirectly.
  • Withings: Withings offers connected health devices including ECG-equipped smartwatches and BPM Core, with FDA-cleared AF detection. It competes for both the consumer heart-monitoring buyer and the clinician-prescribed remote monitoring use case.
  • Apple (Apple Watch ECG): Apple Watch ships FDA-cleared PPG-based irregular rhythm and ECG features to a global consumer installed base. While not a clinical RPM platform, it dominates consumer AF detection mindshare and pressures FibriCheck's DTC channel.

Direct peers

  • iRhythm Technologies: iRhythm's Zio patch provides ambulatory ECG monitoring with AI analysis, competing for the same cardiology-prescribed monitoring budget and clinical workflow that FibriCheck addresses with its PPG smartphone alternative.
  • AliveCor: AliveCor's KardiaMobile is a smartphone/portable ECG device with FDA-cleared AF detection algorithms targeting the same patient-and-provider workflow that FibriCheck serves. It is the closest direct competitor in the smartphone-enabled cardiac rhythm monitoring space.
  • Eko Health: Eko builds FDA-cleared AI-enabled cardiac monitoring tools (digital stethoscope + handheld ECG) with AI algorithms for AF and murmur detection, overlapping FibriCheck's clinical-grade AI cardiac screening positioning.
  • Preventice Solutions (Boston Scientific): Preventice (now part of Boston Scientific) provides remote cardiac monitoring patches and services with AI-driven arrhythmia detection, competing head-to-head with FibriCheck for health system remote monitoring spend.
  • BioTel (Philips): BioTel (formerly BioTelemetry, part of Philips) provides ambulatory cardiac monitoring services (MCOT, Holter) with AI-assisted reporting. It competes directly for cardiology practice and health system remote monitoring contracts.

Emerging players

  • Cardiologs (Philips): Cardiologs offers AI-powered ECG analysis software used by clinicians for arrhythmia detection, integrated into Philips' cardiac monitoring portfolio. It overlaps with FibriCheck's provider-facing AI rhythm interpretation layer.

Regional players

  • Huawei Health: Huawei smartwatches ship PPG-based heart rhythm and ECG features with regulatory approvals in Europe and parts of Asia. It is a comparable PPG-AF wearable play but does not directly target FibriCheck's clinical RPM channel in the US.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

FibriCheck social profiles

Digital presence

FibriCheck compliance and trust

Trust signal

Compliance1 record

FibriCheck financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FibriCheck leadership team

Management profile

Number of profiles

Profiles4 records

FibriCheck funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FibriCheck M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FibriCheck

What does FibriCheck do?

FibriCheck provides an FDA-cleared, smartphone-based heart rhythm monitoring ecosystem that uses photoplethysmography (PPG) signals captured via the smartphone camera to detect atrial fibrillation and other arrhythmias. The offering combines a patient-facing mobile application for 60-second measurements, a clinically validated AI algorithm with 98.5% accuracy for AF detection, a web-based Provider Portal for clinical review and alert management, and an API for integration into EHRs, RPM platforms, and population health systems.

Is FibriCheck a public or private company?

FibriCheck is a private company. It is classified as venture growth investor backed and is currently operating.

When was FibriCheck founded?

FibriCheck was founded in 2014. It employs 11 to 50 people.

Where is FibriCheck based?

FibriCheck is headquartered in Hasselt, Belgium, in the Europe region.

How does FibriCheck make money?

Two revenue lines are on record. Remote Patient Monitoring (RPM) Reimbursement is the primary driver. The others are healthcare System & Health Plan Contracts.

Who are FibriCheck's main competitors?

Broad incumbents on record are Fitbit (Google), Withings and Apple (Apple Watch ECG). Direct peers are iRhythm Technologies, AliveCor, Eko Health, Preventice Solutions (Boston Scientific) and BioTel (Philips). Cardiologs (Philips) is listed as an emerging player. Huawei Health is listed as a regional player.

Does FibriCheck have an API?

Yes. API-based integration into existing EHRs, RPM platforms, and population health systems. The API enables data exchange for rhythm monitoring results and clinical reports within healthcare provider workflows.

What industry is FibriCheck in?

FibriCheck's product category is Remote Cardiac Monitoring Software. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FibricheckFitbit and FibriCheck announce expansion of partnershipFitbit and FibriCheck announced an expansion of their partnership to make the CE-marked FibriCheck heart health app available to Fitbit smartwatch users in France, Germany, Italy, and Spain. The software utilizes Fitbit’s PPG sensors to detect irregular heart rhythms like Atrial Fibrillation, allowing users to share data with medical professionals for diagnosis. This rollout extends the service's availability beyond its initial launch in Belgium, Ireland, the Netherlands, and the UK.MobiHealthNewsHong Kong mobile telemedicine app DrGo adds FibriCheck a-fib screeningDrGo, a mobile telemedicine app by HKT, added FibriCheck, an a-fib screening tool by Qompium, with sensitivity, specificity, and positive predictive values over 90%. The feature delivers results in a minute and triggers follow-up calls from HKSR. HKT launched a free 14-day access program for the first 100,000 users.CW+Cardiology team wins funding for digital innovation projectThe final of the RADICAL digital innovation call was held, with five finalists presenting proposals. FibriCheck, a smartphone atrial fibrillation testing app, won the funding, while Brent Bartholomew's Hololens proposal was runner-up. All finalists will receive funding to test and scale their innovations.MobiHealthNewsFibriCheck announces nighttime a-fib monitoring feature for smartwatch appFibriCheck announced a smartwatch app update that scans for atrial fibrillation while the wearer sleeps, measuring heart rhythm every five minutes. The feature is nearing user testing and will be available to smartwatch manufacturers in the back half of 2020. The company claims its PPG approach is as accurate as ECG-based scans from Apple or AliveCor.